Remote Ischemic Conditioning Using the autoRIC



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:9/2/2018
Start Date:January 30, 2018
End Date:April 2019
Contact:Vera Belaoussoff
Email:vbelaoussoff@cellaegisdevices.com
Phone:647-722-9601

Use our guide to learn which trials are right for you!

Safety and Effectiveness of Remote Ischemic Conditioning With the autoRIC Prior to Elective Percutaneous Coronary Intervention (PCI) Study

The purpose of the study is to evaluate the hypothesis that patients receiving remote
ischemic conditioning using the autoRIC device show statistically significant reduction in
the prevalence of ischemia-reperfusion injury to the myocardium as compared to patients in
the autoRIC Sham device arm (within 12-24 hours post non-emergent PCI with stent
implantation).

This is a multi-center, randomized, controlled single-blind clinical trial to evaluate the
safety and effectiveness of the autoRIC device to attenuate myocardial injury as measured by
cardiac Troponin I (cTnI) levels in patients undergoing PCI with stent implantation.

Eligible patients that are scheduled for an elective PCI, or unscheduled/non-emergent PCI, or
patients scheduled for a diagnostic catheterization procedure with orders of "treat as
indicated" will be enrolled in the study. Patients will undergo remote ischemic conditioning
with the autoRIC device or the control procedure with the autoRIC Sham device completed ≤ 1
hour prior to balloon or stent inflation. Subjects will have measurements of cTnI levels at
baseline and 4-8 and 12-24 hours post completion of the PCI procedure. Adverse events will be
recorded through study exit for all patients. Patients will be exited from the study after
completion of their 30-day post-procedure telephone follow-up.

Inclusion Criteria:

1. Subject is ≥ 18 years of age

2. Subject is scheduled for elective PCI, or unscheduled but non-emergent PCI, or
diagnostic catheterization with PCI if indicated. For non-elective cases, there must
be at least two troponin levels within the upper limit of normal (ULN), at least 6
hours apart prior to the index procedure

3. Subject is willing and capable of providing written informed consent

4. If the subject is a woman of childbearing potential, she must have had a negative
pregnancy test within 24 hours of the study procedure

Exclusion Criteria:

1. Subject requires emergency PCI (i.e., PCI for evolving or ongoing STEMI/NSTEMI)

2. Subject has an elevated troponin level (cTnI or T) > ULN at baseline, based on lab
results obtained from the treating institution

3. Subject is scheduled to undergo PCI with the use of Propofol

4. Subject has a recent history of drug treatment with potassium channel activators
(e.g., Nicorandil) or potassium channel blockers (e.g., sulfonylureas) during the last
7 days prior to baseline

5. Subject had STEMI during the last 4 weeks prior to baseline. (Note: NSTEMI in the last
4 weeks prior to baseline is allowed if the baseline troponin is ≤ ULN.)

6. Underwent a CABG in the last 4 weeks prior to baseline

7. Had a PCI within the last 7 days prior to baseline

8. Subject has a life expectancy < 6 months

9. Subject has NYHA Class IV or decompensated heart failure

10. Subject has peripheral vascular disease requiring intervention during the index
hospitalization or within 4 weeks post-procedure

11. Subject has either serum creatinine >2 times the age-appropriate upper limit of
normal, a glomerular filtration rate (GFR) of < 30 mL/min/1.73m2 or requires dialysis

12. Subject has systolic blood pressure > 200 mmHg

13. Subject is currently being treated with systemic oral or I.V. steroids

14. Subject has a known bleeding disorder or known abnormality of blood flow to the limb
to be treated

15. Subject has peripheral nerve injury, abnormal nerve supply, peripheral neuropathy or
pre-existing traumatic injury to the limb to be treated

16. Subject is scheduled for a PCI procedure to treat a known Chronic Total Occlusion
(CTO) lesion

17. Subject is currently participating in or is planning to participate in another
investigational drug or device trial, prior to the 30-day follow-up visit. (Note:
Observational studies or post-approval studies/ registries, are allowed.)

18. Planned (staged) post-index procedure intervention within 30 days (i.e., PCI of
non-target lesions in any vessel or CABG). (Note: Planned revascularization (PCI or
bypass) of a non-target lesion >30 days following the index procedure is allowed.)

19. Any cardiac surgical procedure planned within 30 days post-enrollment
We found this trial at
15
sites
4401 Wornall Rd
Kansas City, Missouri 64111
(816) 932-2000
Principal Investigator: John Saxon, MD
Phone: 816-932-7528
Saint Luke's Hospital, Kansas City Saint Luke's Hospital is a not-for-profit tertiary referral center committed...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Massoud Leesar, MD
Phone: 205-934-5774
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Cindy Grines, MD
Phone: 516-562-4168
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
Bay Shore, New York 11706
Principal Investigator: Cindy Grines, MD
Phone: 631-968-3016
?
mi
from
Bay Shore, NY
Click here to add this to my saved trials
Brampton, Ontario
Principal Investigator: Shy Amlani, MD
Phone: 905-494-2120
?
mi
from
Brampton,
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Amjad Almahameed, MD
Phone: 704-264-1400
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Danbury, Connecticut 06810
Principal Investigator: Hal Wasserman, MD
Phone: 203-739-7134
?
mi
from
Danbury, CT
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Magdi Ghali, MD
Phone: 515-235-5114
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Gerald Koenig, MD, PhD
Phone: 313-916-1879
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Jacksonville, Florida 32209
Principal Investigator: Andres Pineda Maldonado, MD
Phone: 904-244-2794
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
New York, New York 10029
Principal Investigator: Joseph Sweeney, MD
Phone: 212-241-9687
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10021
Principal Investigator: Cindy Grines, MD
Phone: 212-434-3362
?
mi
from
New York, NY
Click here to add this to my saved trials
Raleigh, North Carolina 27610
Principal Investigator: Mohit Pasi, MD
Phone: 919-784-7695
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
475 Seaview Ave
Staten Island, New York 10305
(718) 226-9000
Principal Investigator: Cindy Grines, MD
Phone: 718-226-1489
Staten Island University Hospital Staten Island University Hospital is a 714-bed, specialized teaching hospital located...
?
mi
from
Staten Island, NY
Click here to add this to my saved trials
West Bloomfield, Michigan 48322
Principal Investigator: Gerald Koenig, MD, PhD
Phone: 248-325-0737
?
mi
from
West Bloomfield, MI
Click here to add this to my saved trials